← Back to news

Markets

Ocular Therapeutix (OCUL) Announces Additional Positive Data From the SOL-1 Phase 3 Superiority Trial of AXPAXLI

Y

Guggenheim Cuts PT on Valneva SE (VALN) to $11 From $13

Y

B. Riley Lifts PT on Theravance Biopharma (TBPH) to $17 From $14

Y

Cantor Fitzgerald Downgrades ADMA Biologics Inc. (ADMA) to Neutral From Overweight

Y

Is Halozyme Therapeutics (HALO) One of the Most Undervalued Biotech Stocks to Buy Right Now?

Y

RBC Capital Lifts PT on Incyte Corporation (INCY) to $95 From $92

Y

Why Royalty Pharma Plc (RPRX) is One of the Most Undervalued Biotech Stocks to Buy Right Now

Y

Raymond James Resumes Coverage of Jazz Pharmaceuticals (JAZZ) With an Outperform Rating

Y

Regeneron Pharmaceuticals (REGN) Announces Collaboration With Telix Pharmaceuticals Limited

Y

AMD: $600 Bullseye

S